Cross-resistance and drug sequence in prostate cancer

Buck, Stefan A.J.; Koolen, Stijn L.W.; Mathijssen, Ron H.J.; Wit, Ronald de; Soest, Robert J. van

doi:10.1016/j.drup.2021.100761

Cited by 55 publications

(28 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemotherapy appears to be a reasonable option for the first-line mCRPC treatment of eligible patients who have previously received ARSi in the mHSPC setting ( Figure 1 b) and in patients with nmCRPC who are progressing during treatment with ARSi. The extent of benefit is unknown due to the lack of prospective studies with this sequence, and clinical data of cross-resistance between ARSi and chemotherapy have been reported [ 48 ].…”

Section: Optimal Sequencing In Mhspc Nmcrpc and Mcrpcmentioning

confidence: 99%

“…Similarly, the analysis of patients included in the COU-AA-302 trial who received docetaxel after abiraterone, consistently with different retrospective series, seems to suggest that the benefit of second-line docetaxel is lower than that observed in patients who received it in first-line [ 53 , 54 ]. Preclinical and clinical data suggest a variable degree of cross-resistance of abiraterone with enzalutamide but also of ARSi with docetaxel [ 48 , 55 , 56 ]; cabazitaxel, on the other hand, retains its clinical activity in patients pretreated with both chemotherapy and ARSi [ 57 , 58 ]. Retrospective data also support the notion that patients with early progression on first-line ARSi show increased response rates and time to PSA progression after treatment with second-line chemotherapy compared to the alternative ARSi [ 59 ].…”

Section: Optimal Sequencing In Mhspc Nmcrpc and Mcrpcmentioning

confidence: 99%

See 1 more Smart Citation

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

Cattrini

España

Mennitto

et al. 2021

Cancers

View full text Add to dashboard Cite

The treatment landscape of advanced prostate cancer has completely changed during the last decades. Chemotherapy (docetaxel, cabazitaxel), androgen-receptor signaling inhibitors (ARSi) (abiraterone acetate, enzalutamide), and radium-223 have revolutionized the management of metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177–PSMA-617 is also going to become another treatment option for these patients. In addition, docetaxel, abiraterone acetate, apalutamide, enzalutamide, and radiotherapy to primary tumor have demonstrated the ability to significantly prolong the survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Finally, apalutamide, enzalutamide, and darolutamide have recently provided impactful data in patients with nonmetastatic castration-resistant disease (nmCRPC). However, which is the best treatment sequence for patients with advanced prostate cancer? This comprehensive review aims at discussing the available literature data to identify the optimal sequencing approaches in patients with prostate cancer at different disease stages. Our work also highlights the potential impact of predictive biomarkers in treatment sequencing and exploring the role of specific agents (i.e., olaparib, rucaparib, talazoparib, niraparib, and ipatasertib) in biomarker-selected populations of patients with prostate cancer (i.e., those harboring alterations in DNA damage and response genes or PTEN).

show abstract

Section: Optimal Sequencing In Mhspc Nmcrpc and Mcrpcmentioning

confidence: 99%

Section: Optimal Sequencing In Mhspc Nmcrpc and Mcrpcmentioning

confidence: 99%

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

Cattrini

España

Mennitto

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…We have previously reported on the impact of androgens and AR signalling on taxane treatment efficacy in CRPC. Taxanes represent a vital therapeutic option for CRPC, however, treatment efficacy is limited by intrinsic and acquired resistance [5]. We showed that testosterone supplementation strongly impairs the activity of both docetaxel and cabazitaxel in vivo [6,7].…”

Section: Introductionmentioning

confidence: 80%

Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

“…These qualitative results are in accordance with what is observed clinically. For example, cross-resistance between androgen receptor signaling inhibitors and taxane chemotherapy has been shown to severely hamper the efficacy of advanced prostate cancer treatment [72]. On the other hand, in a clinical trial for advanced small cell lung cancer, a double bind between a p53 vaccine and chemotherapy led to significantly improved patient outcomes [32,73].…”

Section: Example: Combination Therapy In Cancer (Vector-valued Strategies)mentioning

confidence: 99%

Evolutionary Game Theory: Darwinian Dynamics and the G Function Approach

Bukkuri¹,

Brown²

2021

Games

View full text Add to dashboard Cite

Classical evolutionary game theory allows one to analyze the population dynamics of interacting individuals playing different strategies (broadly defined) in a population. To expand the scope of this framework to allow us to examine the evolution of these individuals’ strategies over time, we present the idea of a fitness-generating (G) function. Under this model, we can simultaneously consider population (ecological) and strategy (evolutionary) dynamics. In this paper, we briefly outline the differences between game theory and classical evolutionary game theory. We then introduce the G function framework, deriving the model from fundamental biological principles. We introduce the concept of a G-function species, explain the process of modeling with G functions, and define the conditions for evolutionary stable strategies (ESS). We conclude by presenting expository examples of G function model construction and simulations in the context of predator–prey dynamics and the evolution of drug resistance in cancer.

show abstract

Cross-resistance and drug sequence in prostate cancer

Cited by 55 publications

References 94 publications

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer

Evolutionary Game Theory: Darwinian Dynamics and the G Function Approach

Contact Info

Product

Resources

About